Scientists finally crack an 'undruggable' pancreatic cancer target, nearly doubling survival rates in landmark trial - Harvard Medical Reports
6 Articles
6 Articles
‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long
A pancreatic cancer drug more than four decades in the making has cracked one of the most stubbornly lethal cancers, extending people's lives and keeping their tumours in check for twice as long as those on regular chemotherapy.
In an unprecedented fact that aroused the enthusiasm and spontaneous ovation of thousands of oncologists at a conference in Chicago, the drug daraxonrasib has proven to be a historic advance against pancreatic cancer.This drug managed to almost double the median survival of patients, raising it from 6.7 to 13.2 months. As it is one of the most aggressive and difficult to combat tumors in today's medicine, this achievement represents an extremely…
Treating pancreatic tumours may have revealed cancer’s master switch
From The Economist Scientists are not usually an excitable bunch. So when many thousands of them recently gave a spontaneous standing ovation (with cheering) in the middle of a lecture, it meant something special happened. At a conference in Chicago at the end of May oncologists went wild over the results of a drug called daraxonrasib, which treats pancreatic cancer. The drug almost doubled median survival times from 6.7 months to 13.2 months. T…
New pill daraxonrasib doubles median survival in patients • This advanced drug effectively blocks growth signals from a mutated gene • Experimental treatment had fewer side effects than chemotherapy
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
